Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
about
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsChronic neutrophilic leukemia: a clinical perspectiveLong-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisA 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic MyelofibrosisEstimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisPrognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.The Calreticulin gene and myeloproliferative neoplasms.Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasmsIncreased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.Calreticulin exon 9 mutations in myeloproliferative neoplasms.High resolution melting analysis: a rapid and accurate method to detect CALR mutations.JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome.Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyJAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution.Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With ThrombocytosisGenetic-pathologic characterization of myeloproliferative neoplasms.Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations.Epidemiology of MPN: what do we know?Calreticulin mutations in myeloproliferative neoplasms.A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Molecular diagnostics of myeloproliferative neoplasms.Advances and challenges in the management of essential thrombocythemia.
P2860
Q26777265-1AFEBD0C-4664-4218-A08F-42675C331B8CQ26781167-803FB681-4200-43E6-AAC4-EBBC92C6A2D1Q27853043-ADC3CE65-89C7-4881-B845-0E406B5DEC31Q28553797-666154F3-1548-414B-8977-5588D18C2983Q30235926-035A9DDB-2FE2-47B9-9129-3E745C648AB1Q31159627-25D7D757-EFA8-4262-BE0E-74C4608329F2Q33416223-726F90AB-134D-4233-868A-8B458B658812Q33432755-B045DFC4-B99F-4681-81D7-7C8137B248CAQ33433481-DE260C19-5AE7-4B77-BB0A-3144EAB7D3B0Q33573793-9EC97FA5-4627-4482-956E-A559BDE7CA3DQ33779135-681E723A-0CC3-480C-B122-F5ADE98F3FA4Q33828563-40568D50-8FB3-41F7-911C-CC6CCAB93069Q34467863-A3DB9082-4C48-4266-8DFE-ADE2F1E4A9ECQ34700714-9EBC2AC3-2D7B-43AB-892E-57CF0391BE86Q34749671-FA299A29-3F81-4391-B636-A70D76020314Q35214151-2A565205-A2F8-40A7-B69A-8BED7E07F00FQ35296834-5BF5D17F-EF9A-4C6A-9E98-FEFB605C5ACAQ35598864-9E6153EF-97AB-44EA-B188-6A5A8BBB4A8BQ35636700-B5116F28-7483-472C-9917-A3F1B3878595Q35778568-DDA89006-B375-45FD-80C3-74235835CFA1Q35800819-41F0D24F-1B86-4769-A36F-1EC9AE586EFDQ35821401-A327E98A-9F6F-4FAC-84F6-8BBF1B0B5AC6Q36169641-69FD2707-8340-46ED-92CE-4C06E3E3DF61Q36502712-6BCCFE59-48C4-4272-B540-874929EA9420Q36541323-AA97D532-99B0-4F8B-A548-CA753A91B415Q36556161-2494CA78-B5EB-48E3-898B-5121D4EC106CQ36782943-8D1AACF2-FE51-4FD8-8879-2647BAE4587FQ36864296-3792BE93-26BF-44E0-8C86-9689A36F6EB8Q37151437-E51D2158-9EC2-4409-B698-86F9085D99DCQ37157892-87546C44-F34E-43CA-8F40-7EF37A02943CQ37555785-4339ACA6-2ACE-41F5-9478-E4CF3573F39DQ37555790-ABEF57CA-48DB-48BF-9756-0FBA0A4611E2Q37636747-2E9D9892-2433-48BA-B692-9C994897CC19Q38210664-63E71F69-277A-41CD-A3B7-51DEB77CA920Q38239217-A8247315-4C17-46DD-98FF-1CCFE8F59031Q38240406-BBE5A759-89AF-4FA3-B472-1E176C5ECD47Q38266905-2119430A-BAC8-4071-A3E0-3732D3CAE8C5Q38300431-AF448FB9-9B6D-41F0-8905-66710314F41CQ38464571-166CE4C1-2417-4DB5-9EB4-6B199CB66287Q38542093-F9535315-DEBF-4C49-AA9B-3CE2C024C27F
P2860
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Impact of calreticulin mutatio ...... in essential thrombocythemia.
@en
Impact of calreticulin mutatio ...... in essential thrombocythemia.
@nl
type
label
Impact of calreticulin mutatio ...... in essential thrombocythemia.
@en
Impact of calreticulin mutatio ...... in essential thrombocythemia.
@nl
prefLabel
Impact of calreticulin mutatio ...... in essential thrombocythemia.
@en
Impact of calreticulin mutatio ...... in essential thrombocythemia.
@nl
P2093
P50
P1433
P1476
Impact of calreticulin mutatio ...... in essential thrombocythemia.
@en
P2093
Alessandro M Vannucchi
Annalisa Pacilli
Associazione Italiana per la R ...... eloproliferative Investigators
Carmela Mannarelli
Giada Rotunno
Tiziana Fanelli
P304
P356
10.1182/BLOOD-2013-11-538983
P407
P577
2013-12-26T00:00:00Z